Aktienanalyse zu STAAR Surgical Co (STAA)STAASTAAR Surgical Co

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also markets and sells an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company's principal products are ICLs used in refractive surgery, including its EVO family of lenses. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).

STAAR Surgical Co is currently a hold. The stock is trading at $21.27, which is below the recent analyst price target of $31 from Stifel, indicating a potential upside of 45.7%. However, the stock has a high forward P/E ratio of 62.5, suggesting it may be overvalued at this time. Additionally, the RSI is at 38.535, indicating that the stock is nearing oversold territory, which could signal a potential rebound. The main risk is the recent negative sentiment, as the stock has dropped 16% over the past year and 9.87% year-to-date, reflecting market caution about its short-term outlook.

5 analysts cover STAA: 3 rate it Buy, 2 Hold and 0 Sell. The average price target is 30.75.